1. INFLUENCE OF HCV GENOTYPE 1 SUBTYPES ON THE VIRUS RESPONSE TO PEG INTERFERON ALPHA-2a PLUS RIBAVIRIN THERAPY
- Author
-
Sophie Thebault, Etienne Chatelut, Jean-Louis Payen, Christophe Renou, Laurent Alric, Jean-Jacques Meurisse, Jacques Izopet, Yves Imbert, Daniel Garipuy, Florence Nicot, Thierry Morin, B. Castan, Karine Sauné, Stéphane Sire, Jean-Marc Combis, Bruno Guérin, Karl Barange, Hervé Desmorat, Jean-Michel Dramard, S. Metivier, Jean-Marie Peron, Pierre Barel, Virology Laboratory, Hospital, Département d'hépatologie et de gastroentérologie, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Gastroenterology, Toulouse University hospital, Val d'Ariège Hospital, Ambroise Paré Cinic, General Medicine, Internal Medicine, Ducuing Hospital, Polyclinique du Parc, Hepato-gastro-enterology, Bigorre Hospital, Hepatology, Hopital, Laboratory of Virology, EA3035, Institut Claudius Regaud, VIROLOGIE, and CHU Toulouse [Toulouse]
- Subjects
Adult ,Male ,Genotype ,Hepacivirus ,Hepatitis C virus ,HIV Infections ,medicine.disease_cause ,Antiviral Agents ,Polyethylene Glycols ,03 medical and health sciences ,chemistry.chemical_compound ,Flaviviridae ,0302 clinical medicine ,Pegylated interferon ,Virology ,Ribavirin ,Medicine ,Humans ,030212 general & internal medicine ,Prospective Studies ,Prospective cohort study ,030304 developmental biology ,Aged ,0303 health sciences ,biology ,business.industry ,Interferon-alpha ,virus diseases ,Hepatitis C ,Hepatitis C, Chronic ,Middle Aged ,Viral Load ,biology.organism_classification ,medicine.disease ,Recombinant Proteins ,digestive system diseases ,3. Good health ,Infectious Diseases ,Treatment Outcome ,chemistry ,Drug Therapy, Combination ,Female ,Viral disease ,business ,medicine.drug - Abstract
International audience; New factors that influence the viral response in HCV non-genotype 2/3 patients must be identified in order to optimize anti-HCV treatment. This multicenter prospective study evaluates the influence of HCV variability and pharmacological parameters on the virological response of these patients to pegylated interferon α2a (peg-IFN-α2a: 180 µg/week) and ribavirin (800-1200 mg/day) for 48 weeks. HCV subtypes were identified by sequencing the NS5B region. Serum ribavirin and peg-IFN-α2a concentrations were measured at weeks 4 and 12. The 115 patients (67 men; median age=49, range [31-76]) included 64 who had never been treated and 27 co-infected with HIV. The mean baseline HCV RNA was 6.30 ± 0.06 log IU/mL and the HCV genotypes were: G1 (n=93) with 1a (n=37) and 1b (n=50), G4 (n=20) and G5 (n=2). Most patients (79/108; 73%) had an early virological response. Independent predictors of an early virological response were interferon naive patients (OR=2.98 [1.15; 7.72]) and ribavirin of > 2,200 ng/mL at week 12 (OR=3.41 [1.31; 8.90]). Forty of 104 patients (38%) had a sustained virological response. The only independent predictors of a sustained virological response were subtype 1b (OR=6.82 [1.7; 26.8]), and HCV RNA 2,200 ng/mL was associated with an early virological response and patients infected with HCV subtype 1b had a better chance of a sustained virological response than did those infected with subtype 1a.
- Published
- 2011
- Full Text
- View/download PDF